[
  {
    "ts": null,
    "headline": "Top Analyst Reports for AbbVie, RTX & IBM",
    "summary": "AbbVie leads today's top analyst picks after beating Q4 estimates, while RTX and IBM also draw attention for strong results and growth drivers.",
    "url": "https://finnhub.io/api/news?id=4f819e87b7789b06f4a128822de53de54eb23853514bf383c3497d050a141a21",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771362780,
      "headline": "Top Analyst Reports for AbbVie, RTX & IBM",
      "id": 139127308,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie leads today's top analyst picks after beating Q4 estimates, while RTX and IBM also draw attention for strong results and growth drivers.",
      "url": "https://finnhub.io/api/news?id=4f819e87b7789b06f4a128822de53de54eb23853514bf383c3497d050a141a21"
    }
  },
  {
    "ts": null,
    "headline": "Assessing AbbVie (ABBV) Valuation After Strong Results And New Rinvoq Vitiligo Filings",
    "summary": "AbbVie (ABBV) is back in focus after releasing fourth quarter and full year 2025 results, alongside fresh regulatory filings for Rinvoq in vitiligo that highlight how its growth engine extends beyond the Humira era. See our latest analysis for AbbVie. The recent 1 month share price return of 8% and 7 day gain of 4.07% suggest momentum has picked up again after a flat 90 day patch. At the same time, the 1 year total shareholder return of 21.92% and 5 year total shareholder return of 163.78%...",
    "url": "https://finnhub.io/api/news?id=f2c0e8ad49f19e686145a6ad0807cc1f7f0ada102d8c0127e001d9902767ec61",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771362608,
      "headline": "Assessing AbbVie (ABBV) Valuation After Strong Results And New Rinvoq Vitiligo Filings",
      "id": 139126561,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) is back in focus after releasing fourth quarter and full year 2025 results, alongside fresh regulatory filings for Rinvoq in vitiligo that highlight how its growth engine extends beyond the Humira era. See our latest analysis for AbbVie. The recent 1 month share price return of 8% and 7 day gain of 4.07% suggest momentum has picked up again after a flat 90 day patch. At the same time, the 1 year total shareholder return of 21.92% and 5 year total shareholder return of 163.78%...",
      "url": "https://finnhub.io/api/news?id=f2c0e8ad49f19e686145a6ad0807cc1f7f0ada102d8c0127e001d9902767ec61"
    }
  },
  {
    "ts": null,
    "headline": "Facial Injectable Analysis Report 2025: An $18.89 Billion Market by 2029, Driven by New Product Launches, Emerging Markets, AI Innovations, Male Aesthetics, Younger Demographics",
    "summary": "Key applications of facial injectables include wrinkle reduction, facial line correction, and enhancement of facial features. The market is segmented by type (Derma Fillers and Neuromodulator Aesthetics), application (Facial Line Correction, Face Lift), and end-users. North America leads the market share due to technological advancements and high consumer awareness, while the Asia Pacific region is expected to witness the fastest growth. Key players like AbbVie, Ipsen, and Galderma are expanding",
    "url": "https://finnhub.io/api/news?id=d392f9a0f5de942f67d843c2c4a4ba968d58c0cf855fe4779f5ed050c311e991",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771342320,
      "headline": "Facial Injectable Analysis Report 2025: An $18.89 Billion Market by 2029, Driven by New Product Launches, Emerging Markets, AI Innovations, Male Aesthetics, Younger Demographics",
      "id": 139123960,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Key applications of facial injectables include wrinkle reduction, facial line correction, and enhancement of facial features. The market is segmented by type (Derma Fillers and Neuromodulator Aesthetics), application (Facial Line Correction, Face Lift), and end-users. North America leads the market share due to technological advancements and high consumer awareness, while the Asia Pacific region is expected to witness the fastest growth. Key players like AbbVie, Ipsen, and Galderma are expanding",
      "url": "https://finnhub.io/api/news?id=d392f9a0f5de942f67d843c2c4a4ba968d58c0cf855fe4779f5ed050c311e991"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Down Since Q4 Earnings Report: How to Play the Stock",
    "summary": "ABBV stock declines since it announced earnings results on Feb. 4. Skyrizi and Rinvoq fuel growth, offsetting Humira erosion.",
    "url": "https://finnhub.io/api/news?id=92bd175d0f32a0e0fb04227bca20e9dc19a05be6e178f06dcce127e222d25874",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771336620,
      "headline": "AbbVie Down Since Q4 Earnings Report: How to Play the Stock",
      "id": 139123920,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "ABBV stock declines since it announced earnings results on Feb. 4. Skyrizi and Rinvoq fuel growth, offsetting Humira erosion.",
      "url": "https://finnhub.io/api/news?id=92bd175d0f32a0e0fb04227bca20e9dc19a05be6e178f06dcce127e222d25874"
    }
  },
  {
    "ts": null,
    "headline": "10 Health Care Stocks With Whale Alerts In Today's Session",
    "summary": "",
    "url": "https://finnhub.io/api/news?id=bc69404b67565b1e405444a3527ed916cb98692284a20d4aec92df712a69cb1b",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771335327,
      "headline": "10 Health Care Stocks With Whale Alerts In Today's Session",
      "id": 139133638,
      "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_3.jpg?width=2048&height=1536",
      "related": "ABBV",
      "source": "Benzinga",
      "summary": " ",
      "url": "https://finnhub.io/api/news?id=bc69404b67565b1e405444a3527ed916cb98692284a20d4aec92df712a69cb1b"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie: Dominating Immunology While Building Oncology Upside",
    "summary": "The total net revenues of AbbVie's Rinvoq and Skyrizi were about $25.87 billion in 2025, up 46.2% from 2024. Read why ABBV stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=d0d43a6522bc4e441a8332fdd53d2e63617ad866a0c0b56eb5e1f8a2822d2878",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771290687,
      "headline": "AbbVie: Dominating Immunology While Building Oncology Upside",
      "id": 139119790,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1398519163/image_1398519163.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "The total net revenues of AbbVie's Rinvoq and Skyrizi were about $25.87 billion in 2025, up 46.2% from 2024. Read why ABBV stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=d0d43a6522bc4e441a8332fdd53d2e63617ad866a0c0b56eb5e1f8a2822d2878"
    }
  }
]